Curis (CRIS) Shares Outstanding (Diluted Average) (2010 - 2026)
Curis (CRIS) reported Shares Outstanding (Diluted Average) of $19.4 million for Q1 2026, up 127.97% on a YoY basis from $8.5 million in Q1 2025, and up 47.09% quarter-over-quarter from $13.2 million in Q4 2025.
Curis (CRIS) Shares Outstanding (Diluted Average) (2010 - 2026) Analysis & Trends
Curis has reported Shares Outstanding (Diluted Average) for 11 years, with the latest figure at $19.4 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 127.97% year-over-year to $19.4 million; the trailing twelve-month figure through Mar 2026 stood at $19.4 million (up 127.97% YoY), and the FY2025 full-year result was $13.2 million, up 108.74% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $19.4 million, up from $13.2 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $91.7 million in Q2 2022, with the low at $4.6 million in Q3 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $17.8 million across 5 years, with a median of $5.9 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) plunged 94.96% — and 2026, when it surged 127.97%.
- Curis' Shares Outstanding (Diluted Average) stood at $4.7 million in 2022, then climbed by 13.36% to $5.3 million in 2023, then advanced by 19.14% to $6.3 million in 2024, then jumped by 108.74% to $13.2 million in 2025, then surged by 47.09% to $19.4 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $19.4 million (Q1 2026), $13.2 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 92.44 Mn |
| 10 | Curis | 8.58 Mn | -6.42 Mn | - | 19.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.36 Mn |
| Dec 31, 2025 | 13.16 Mn |
| Sep 30, 2025 | 12.29 Mn |
| Jun 30, 2025 | 12.63 Mn |
| Mar 31, 2025 | 8.49 Mn |
| Dec 31, 2024 | 6.31 Mn |
| Sep 30, 2024 | 5.94 Mn |
| Jun 30, 2024 | 5.82 Mn |
| Mar 31, 2024 | 5.78 Mn |
| Dec 31, 2023 | 5.29 Mn |
| Sep 30, 2023 | 5.72 Mn |
| Jun 30, 2023 | 4.83 Mn |
| Mar 31, 2023 | 4.83 Mn |
| Dec 31, 2022 | 4.67 Mn |
| Sep 30, 2022 | 4.62 Mn |
| Jun 30, 2022 | 91.65 Mn |
| Mar 31, 2022 | 91.65 Mn |
| Dec 31, 2021 | 91.57 Mn |
| Sep 30, 2021 | 91.60 Mn |
| Jun 30, 2021 | 91.55 Mn |